Topical Collection "Stem Cells and Cancer Therapeutics"

Editors

Guest Editor
Dr. Lluis Espinosa

Stem Cells and Cancer Research Laboratory, CIBERONC. Institut Hospital del Mar Investigacions Mèdiques (IMIM), 08003 Barcelona, Spain
Website | E-Mail
Interests: signaling pathways; NF-kappaB; Notch; intestinal stem cells; colorectal cancer
Guest Editor
Dr. Anna Vert

Stem Cells and Cancer Research Laboratory, CIBERONC. Institut Hospital del Mar Investigacions Mèdiques (IMIM), 08003 Barcelona, Spain
Website | E-Mail
Interests: patient-derived tumoroids; therapy resistance; intestinal cancer; drug discovery

Topical Collection Information

Dear Colleagues,

Stems cells are defined as cells with the ability to self-renew and to differentiate into multiple lineages. This definition applies to both physiologic and pathologic conditions such as cancer, although functional differences in these cell populations crucially impact on their behavior. In the case of cancer, multiple experimental pieces of evidence support the existence of specific cell populations that are functionally identified for their capacity to initiate and propagate tumors. These cells have been classically called tumor initiating cells (TICs) or cancer stem cells (CSCs) and are supposed to possess stem cell-like properties, including long-term self-renewal, capacity of multi-lineage differentiation, increased resistance to therapy, and the ability to promote tumor relapse and metastasis. As in normal stem cells, essential developmental related pathways such as Wnt, Notch, Hedgehog, NF-kappaB, or JAK/STAT participate in supporting TIC capacity. This Special Issue will focus on understanding the molecular mechanisms that control normal and cancer-related stemness and the tools that are currently available for studying them both in vitro and in vivo. In particular, we will pay attention to how TICs contribute to cancer progression and therapy resistance, and the possibility of specifically targeting TIC in anti-cancer therapies.

Dr. Lluis Espinosa
Dr. Anna Vert
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Signaling pathways in normal and tumor stem cells
  • Cancer stem cells and their biology
  • Stem cells and metastasis
  • In vivo models for studying normal and cancer stem cells
  • In vitro models for studying normal and cancer stem cells
  • Targeting cancer stem cells

Published Papers

This collection is now open for submission.
Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top